The Health Ministry in India has recommended that a compulsory licence (CL) is issued for the manufacture of Bristol-Myers Squibb’s (BMS) anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Sprycel, India, Patent, WTO TRIPS, Compulsory Licence,
